neutral
2 days agoNatco Pharma jumps over 5% after ratings reaffirmation boosts investor confidence
Trading activity in Natco Pharma turned upbeat on Monday after ICRA reaffirmed and assigned credit ratings for several of the company’s debt instruments, signalling continued financial stability. The stock climbed 5 percent intraday to ₹922.15 on the BSE, extending a sharp recovery that has lifted shares nearly 40 percent from the April low of ₹660.05.
Tags:
- natco pharma
- icra
Explore:Mutual Fund Screening
neutral
2 days agoNatco Pharma jumps over 5% after ratings reaffirmation boosts investor confidence
Trading activity in Natco Pharma turned upbeat on Monday after ICRA reaffirmed and assigned credit ratings for several of the company’s debt instruments, signalling continued financial stability. The stock climbed 5 percent intraday to ₹922.15 on the BSE, extending a sharp recovery that has lifted shares nearly 40 percent from the April low of ₹660.05.
Tags:
- natco pharma
- icra
Explore:Mutual Fund Screening
1 min read
55 words
Natco Pharma gained over 5% after ICRA reaffirmed its credit ratings, driving heavy trade and renewed interest as the stock continued a multi-month recovery.
Trading activity in Natco Pharma turned upbeat on Monday after ICRA reaffirmed and assigned credit ratings for several of the company’s debt instruments, signalling continued financial stability. The stock climbed 5 percent intraday to ₹922.15 on the BSE, extending a sharp recovery that has lifted shares nearly 40 percent from the April low of ₹660.05.
Trading activity in Natco Pharma turned upbeat on Monday after ICRA reaffirmed and assigned credit ratings for several of the company’s debt instruments, signalling continued financial stability. The stock climbed 5 percent intraday to ₹922.15 on the BSE, extending a sharp recovery that has lifted shares nearly 40 percent from the April low of ₹660.05.
Tags:
- natco pharma
- icra
- natco pharma
- icra
- rating update
- pharma stocks
Dec 1, 2025 • 09:25